← SynDRA
NABUMETONE
SynDRA canonical compound SYN0003502 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PTGS2 |
|---|
| Mechanism of action | Cyclooxygenase inhibitor |
|---|
| Indication | osteoarthritis | rheumatoid arthritis |
|---|
| Disease area | rheumatology |
|---|
All known targets
- PTGS2
- PTGS1
- AKR1C3
- CYP1A2
- CYP2B6
- CYP2C19
- CYP2E1
- MAOA
- SLC6A2
Mechanisms of action (all sources)
- Cyclooxygenase inhibitor
- PTGS2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ESR1
- SLC6A3
- NR1I2
- ACHE
- MAPK14
- NPY1R
- NPC1
- NFE2L2
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPT
- MAPK3
- LMNA
- MAPK1
- LCK
- KDM4E
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH2
- NPY2R
- NR3C1
- HMGCR
- OPRD1
- USP1
- TP53
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SMN1
- SLCO1B3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AHR
- KCMB2
- RPGF4
- RARA
- PRGR
- NR0B1
- NF2L2
- KCMB4
- KCMB1
- ATAD5
- KCMA1
- HDAC9
- ESRRA
- CSTA
- CP2CJ
- CP1A2
- SMN
Drug classes
- Cyclooxygenase Inhibitors
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Cyclooxygenase 2 Inhibitors
- Enzyme Inhibitors
- Peripheral Nervous System Agents
- Sensory System Agents
- Nonsteroidal Anti-inflammatory Drug
ATC classes
- M01A · ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Cross-references
Synonyms
- RELAFEN
- Relafen
- nabucox
- nabumeton
- nabuton
- Nabumetona
- BRL-14777
- NSC-758623
- Relifex
- NNB-001
- NNB-004
- NNB-005
- Nabumetone (oral)
- Nabumetone (oral), Nobex
- 6-MNA (oral), Nobex
- nabumetone (usp-rs)
- BRL 14777
- nabumetone (ep monograph)
- nabumetone (usp impurity)
- LW0TIW155Z
- NSC 758623
- nabumetone (usp monograph)
- Nabumetonum
- CHEBI:7443
- DTXCID2025472
- Nabumetone [USAN:USP:INN:BAN:JAN]
- ApoNabumetone
- Rhoxal nabumetone
- Nabumetone (USAN:USP:INN:BAN:JAN)
- Nabumetone 500 mg
- Nabumetone 750 mg
- RELAFEN DS
- Nabumetone 1000 mg
- RefChem:55684
- M01AX01
- Arthaxan
- Relifen
Reported adverse events
- Hypersensitivity
- Stevens-Johnson syndrome
- Albuminuria
- Dizziness
- Nightmare
- Pruritus
- Thrombocytopenia
- Tinnitus
- Vasculitis
- Bilirubinuria
- Acne
- Anaphylactoid reaction
Look up NABUMETONE in the interactive SynDRA portal →